Molecule Name |
DB09313
|
DrugBank Groups |
Approved
|
Cluster No |
1168
|
Smiles |
IC1(=C(N(C(=O)C)C)C(I)=C(C(=O)NC)C(=C1C(=O)NCC(=O)NC2(=C(I)C(=C(I)C(=C2I)C(=O)NCCO)C(=O)O))I)
|
Download |
mol2, pdbqt
|
TPSA |
194,24
|
Non-H Atoms |
43
|
Non-C/H Atoms |
19
|
Metal-Atoms |
0
|
Electronegative Atoms |
19
|
Stereo Centers |
0
|
Rotatable Bonds |
10
|
Rings Closures |
2
|
Small Rings |
2
|
Aromatic Rings |
2
|
Aromatic Atoms |
12
|
sp3-Atoms |
8
|
Symmetric atoms |
0
|
cLogS |
-9,125
|
MW |
1268,86
|
cLogP |
2,3088
|
HBA |
13
|
HBD |
6
|
Ro5 violations |
3
|
Druglikeness |
5,3079
|
DrugScore |
0,147199045858691
|
Mutagenic |
high
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
none
|
Blood-Brain Barrier |
BBB-
|
Human Intestinal Absorption |
HIA-
|
Caco-2 Permeability |
Caco2-
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Non-inhibitor
|
P-glycoprotein Inhibitor 2 |
Non-inhibitor
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Aqueous solubility |
-3,4871
|
Caco-2 Permeability 2 |
0,6924
|
Subcellular localization |
Mitochondria
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 2D6 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 1A2 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 2C19 Inhibitor |
Non-inhibitor
|
CYP450 3A4 Inhibitor |
Non-inhibitor
|
CYP Inhibitory Promiscuity |
Low CYP Inhibitory Promiscuity
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition 2 |
Non-inhibitor
|
AMES Toxicity |
Non AMES toxic
|
Carcinogens |
Non-carcinogens
|
Fish Toxicity |
High FHMT
|
Fish Toxicity (pLC50, mg/L) |
1,1551
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity (pIGC50, ug/L) |
0,6551
|
Honey Bee Toxicity |
Low HBT
|
Biodegradation |
Not ready biodegradable
|
Acute Oral Toxicity |
IV
|
Rat Acute Toxicity (LD50, mol/kg) |
1,9538
|
Carcinogenicity (Three-class) |
Non-required
|